Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus

Highlights ► Our analysis suggests that vaccinating girls against CMV is costs less and has greater clinical benefit than not vaccinating. ► Vaccination costs $32.3million dollars less than not vaccinating for each 100,000 girls. ► When vaccine efficacy against neonatal disease is less than 61%, not...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-06, Vol.30 (27), p.4060-4066
Main Authors: Dempsey, Amanda F, Pangborn, Heidi M, Prosser, Lisa A
Format: Article
Language:English
Subjects:
Adolescence
Adolescent
adolescents
Allergy and Immunology
Child
Children
Cost-Benefit Analysis
Cost-effectiveness
Cytomegalovirus
Cytomegalovirus Infections - congenital
Cytomegalovirus Infections - economics
Cytomegalovirus Infections - prevention & control
Cytomegalovirus Vaccines - administration & dosage
Cytomegalovirus Vaccines - economics
Cytomegalovirus Vaccines - immunology
decision support systems
Female
females
hearing disorders
Hearing loss
Humans
Infant
Infant, Newborn
Infants
Infection
Mental retardation
Morbidity
Mortality
Pregnancy
Teenagers
Vaccination
Vaccination - economics
Vaccination - methods
Vaccine
Vaccines
Vision
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Our analysis suggests that vaccinating girls against CMV is costs less and has greater clinical benefit than not vaccinating. ► Vaccination costs $32.3million dollars less than not vaccinating for each 100,000 girls. ► When vaccine efficacy against neonatal disease is less than 61%, not vaccinating becomes the preferred strategy.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.04.011